Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

PURPOSE: Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML). PATIENTS AND METHODS: A total of 50...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Cortes, Jorge E., Kim, Dong-Wook, Kantarjian, Hagop M., Brümmendorf, Tim H., Dyagil, Irina, Griskevicius, Laimonas, Malhotra, Hemant, Powell, Christine, Gogat, Karïn, Countouriotis, Athena M., Gambacorti-Passerini, Carlo
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2012
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979199/
https://ncbi.nlm.nih.gov/pubmed/22949154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.38.7522
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items